BELLUS Health Inc. is engaged in developing drugs for rare diseases starting with conditions that affect the kidneys. The Company's lead program is KIACTA, a drug candidate in a Phase III Confirmatory Study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. KIACTA is also being developed as a treatment in a second indication called sarcoidosis, a rare inflammatory condition that affects the lungs. In addition, the Company is developing Shigamab, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS). sHUS often leads to dialysis, chronic kidney disease and in some cases death, particularly in children. Its pipeline also includes a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body.